Literature DB >> 7664291

Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.

C Pyke1, S Salo, E Ralfkiaer, J Rømer, K Danø, K Tryggvason.   

Abstract

Recombinant human gamma 2 chain of laminin-5 was expressed in Escherichia coli, and used to generate specific polyclonal antibodies which were used to study the distribution of the protein in human cancers. A total of 72 biopsies of human cancers were stained, including 23 cases of colon adenocarcinomas, 16 ductal breast carcinomas, 9 malignant melanomas, 14 squamous cell carcinomas of the skin and cervix, and 10 sarcomas. As a control for the specificity of the antibodies, we performed in situ hybridization on adjacent sections of a number of the cases, and in all of these cases the localization of the gamma 2 chain protein and mRNA was identical. We found gamma 2 chain immunoreactivity in cancer cells in all cases of colon adenocarcinomas and squamous cell carcinomas but not in any of the sarcomas, supporting the view that the laminin-5 protein is specific for cells of epithelial origin. Notably, in all of the cases of colon adenocarcinomas, the positive staining was invariably associated with budding cancer cells located at the tip of invading malignant epithelium, whereas the cancer cells deeper in the tumors were most often negative. The staining was cytoplasmic in all cases and only in one case did we see additional extracellular immunoreactivity, indicating that this laminin isoform in cancer tissue is not laid down in the extracellular matrix but probably exerts its function at the cell surface or in its immediate vicinity. Using in situ hybridization to analyze the coexpression of laminin-5 and components of the plasminogen activation system, we found that the histological distribution of laminin-5-positive budding cancer cells at the invasion front in colon adenocarcinomas was identical to that of the receptor for urokinase-type plasminogen activator. These findings suggest that laminin-5 is a marker of invading cancer cells in at least some human malignancies, and that it therefore might represent a valuable marker for the invasive potential of these cancers. The colocalization of laminin-5 and urokinase-type plasminogen activator receptor in a subset of cancer cells in colon cancer also suggests that a controlled up-regulation of a number of gene products is a characteristic of budding colon cancer cells, and that these gene products serve functions crucial for the invasive phenotype of these cancer cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664291

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  95 in total

1.  RhoA-dependent switch between alpha2beta1 and alpha3beta1 integrins is induced by laminin-5 during early stage of HT-29 cell differentiation.

Authors:  S P Gout; M R Jacquier-Sarlin; L Rouard-Talbot; P Rousselle; M R Block
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

2.  Laminin-5 gamma2 chain expression as a possible determinant of tumor aggressiveness in T1 colorectal carcinomas.

Authors:  Tadahiko Masaki; Hiroyoshi Matsuoka; Masanori Sugiyama; Nobutsugu Abe; Yumi Izumisato; Atsuhiko Sakamoto; Yutaka Atomi
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

3.  ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells.

Authors:  Justin M Drake; J Matthew Barnes; Joshua M Madsen; Frederick E Domann; Christopher S Stipp; Michael D Henry
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

Review 4.  Tumour budding in colorectal cancer: what do we know and what can we do?

Authors:  Linde De Smedt; Sofie Palmans; Xavier Sagaert
Journal:  Virchows Arch       Date:  2015-11-27       Impact factor: 4.064

5.  Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis.

Authors:  Jennifer S Davids; Adelaide M Carothers; Beatrice C Damas; Monica M Bertagnolli
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

6.  Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease.

Authors:  Christiane Mühle; Qiu-Jie Jiang; Alexandra Charlesworth; Leena Bruckner-Tuderman; Guerrino Meneguzzi; Holm Schneider
Journal:  Hum Genet       Date:  2004-11-05       Impact factor: 4.132

7.  Distribution of basement membrane anchoring molecules in normal and transformed endometrium: altered expression of laminin gamma2 chain and collagen type XVII in endometrial adenocarcinomas.

Authors:  Marko Määttä; Sirpa Salo; Kaisa Tasanen; Ylermi Soini; Annikki Liakka; Leena Bruckner-Tuderman; Helena Autio-Harmainen
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

8.  Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis).

Authors:  Emma Pirilä; Nungavarm S Ramamurthy; Timo Sorsa; Tuula Salo; Jarkko Hietanen; Päivi Maisi
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

9.  Laminin-5 gamma2-chain expression and DNA ploidy as predictors of prognosis in endometrial carcinoma.

Authors:  C Lundgren; B Frankendal; C Silfverswärd; B Nilsson; K Tryggvason; G Auer; B Nordström
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 10.  Laminin-5 in epithelial tumour invasion.

Authors:  Masahiko Katayama; Kiyotoshi Sekiguchi
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.